GOT1, glutamic-oxaloacetic transaminase 1, 2805

N. diseases: 71; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE The screening revealed that inhibitors of Hsp90 can potentiate the tumour cell-killing effect of radiation in a synergistic fashion (GOT1; false discovery rate <3.2×10-11). 30730850 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE Previous studies on nude mice bearing the human small intestine neuroendocrine tumor, GOT1, have shown that a priming injection of <sup>177</sup>Lu-octreotate 24 h before the main injection of <sup>177</sup>Lu-octreotate resulted in higher <sup>177</sup>Lu concentration in tumor, resulting in increased absorbed dose, volume reduction, and time to regrowth. 30895393 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 AlteredExpression group BEFREE Furthermore, downregulation of GOT1 counteracted the effects of miR-9-5p repression, whereas its overexpression reversed tumor inhibitory effects of miR-9-5p. 30591220 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. 27871087 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 AlteredExpression group BEFREE <i>CCAT-1</i> expression was related to the stage and size of the tumor and recurrence prognosis. 28978096 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE A CRC subcutaneous tumor model was performed to determine the impact of GOT1 inhibition on 5-FU efficacy in vivo. 28314989 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE Shorter overall survival was associated with high expression of GLUT1 in tumor (P = 0.002) and GOT1 in tumor (p = 0.030). 25719198 2015